Tissue Regenix Group PLC Issue of Equity (1940A)
December 22 2017 - 4:30AM
UK Regulatory
TIDMTRX
RNS Number : 1940A
Tissue Regenix Group PLC
22 December 2017
Tissue Regenix Group Plc
Issue of equity and total voting rights
Leeds, 22 December 2017 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix" or "the Company"), the regenerative medical
devices company, announces that it has today issued and allotted
8,307,608 ordinary shares of 0.5p each in the Company, following an
exercise of options which were granted in respect of a 2010 EMI
award.
The 8,307,608 new ordinary shares will rank pari passu with the
existing ordinary shares and application has been made for these
new ordinary shares to be admitted to trading on AIM. It is
expected that Admission will occur at 8:00a.m. on Friday 29
December 2017.
Total Voting Rights
Following the issue of the 8,307,608 new ordinary shares, the
Company will have a total of ordinary 1,170,990,924 ordinary shares
of 0.5p each in issue. The above figure may be used by shareholders
in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change in their interest in, the share capital of the
Company under the FCA's Disclosure and Transparency Rules.
For more Information:
Tissue Regenix Group plc Tel: 0330
Steve Couldwell CEO 430 3073
Caitlin Pearson Head of Communications / 07920272441
======================================== ================
Jefferies International Ltd Tel: 020
Simon Hardy / Chris Binks 7029 8000
FTI Consulting Tel: 0203
Brett Pollard/ Mo Noonan / Rob Winder 727 1000
======================================== ================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEKLLBLDLFBFBE
(END) Dow Jones Newswires
December 22, 2017 04:30 ET (09:30 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2023 to Apr 2024